

Appendix 3: Teaching case for interprofessional group discussion

Managing polypharmacy in a 77-year-old woman with multiple prescribers

Barbara Farrell BScPhm PharmD, Véronique French Merkle MD, Wade Thompson HBSc

This teaching case includes instructions and worksheets to facilitate interprofessional group discussion about the management of polypharmacy.

A 77-year-old woman was referred to a geriatric day hospital with concerns about mobility and falls, pain, constipation, cognition and polypharmacy. Comorbidities included cerebrovascular disease, coronary artery disease, hypertension, dementia, fibromyalgia, myositis, bipolar disorder, arthritis, remote duodenal ulcer and hypothyroidism. A stroke 3 years earlier resulted in increasing difficulties with transfers and ambulation, leading to 3–4 falls weekly. Chronic pain was attributed to fibromyalgia. The patient was frustrated by her loss of independence, because she now required daily assistance with washing and dressing. Staff at her retirement residence managed her complex medication regimen (see Box 1 for the list of medications). Placement in a long-term care facility was being considered.

At presentation, the patient was wheelchair-bound and heavily sedated, which made the interview and assessment difficult. She had had near-falls while attempting to transfer herself from her wheelchair and was unable to stand unsupported. Orthostatic hypotension was noted (drop in blood pressure from 118/64 mm Hg while reclining to 80/50 mm Hg after standing).

The patient accepted a 12-week admission to the geriatric day hospital, and twice-weekly transportation was organized. A multidisciplinary team, including a pharmacist, a nurse, a social worker, an occupational therapist and a physiotherapist, was consulted. Results of bloodwork were normal except for a low calcium level (2.17 [normal 2.20–2.65] mmol/L). Using the Cockcroft–Gault equation with ideal body weight, we calculated her creatinine clearance to be 30 mL/min, which we considered to be low for her age.

Initial visits led to the development of an

interprofessional plan. The pharmacist assessed the medication list, evaluating each medication for indication, effectiveness, safety, compliance and patient understanding.¹ The patient's personal experience with medications was difficult to ascertain because of her sedation. Results of the initial medication assessment are outlined in Appendix 3A.

Stop here: If you are using this case report for group discussion, see the end of the article (Appendix 3B) for instructions, discussion questions and a blank worksheet. You may print out the case description and Appendix 3A for discussion before reading about the results of the medication assessment.

Signs and symptoms were assessed to identify drug-related causes.² The complete medication assessment is outlined in Box 2.

Stop here: If you are using this case report for group discussion, see the end of the article (Appendix 3C) for instructions, discussion questions and a blank worksheet. You may print out the case description and Box 2 for discussion before reading about how the care plan was implemented.

KEY POINTS

- Medications are potential contributors to geriatric syndromes such as falls and cognitive impairment.
- The risk of falls can be increased with certain drug classes such as antihypertensives, central nervous system depressants and cardiovascular agents.
- Drugs with anticholinergic properties can have additive effects, with the result being a high anticholinergic load.
- Different classes of medications can be successfully stopped concomitantly; careful planning is required to avoid and monitor for adverse events related to drug withdrawal.
- Communication between health care professionals will improve medication selection and avoid doses that contribute to functional difficulties in older patients.

Competing interests: See end of article.

This article has been peer reviewed.

Correspondence to: bfarrell@bruyere.org

CMAJ 2013, DOI:10.1503/cmaj.122012

Throughout the admission, several medication changes were made (Appendix 3D). The patient participated in physiotherapy and exercise to address deconditioning. The occupational therapist reviewed daily activities and fall-prevention strategies. The patient's leg strength and balance improved (her Berg Balance score increased from 18 to 31 out of 56). She progressed from using a wheelchair to walking 150 m with a cane. No falls were reported from the fourth week of admission onward.

Despite a reduction in her analgesic medications, her pain did not worsen, in part because nonpharmacologic coping strategies were used. She reported having increased self-confidence and independence in daily activities. Her consti-

pation resolved. She became much more alert and resumed old hobbies such as knitting. The social worker provided supportive counselling sessions, and the patient incorporated relaxation strategies into her daily routine. The patient's mobility and cognition improved, and she sought opportunities to interact with other patients and participate in activities. She reported improved nighttime sleeping and no more daytime napping. Once medications affecting cognition were minimized, a reassessment with neuropsychology ultimately showed findings in keeping with the size and location of her stroke, but no dementia.

The patient's daily pill burden decreased from 32 to 17 pills by the end of the 12-week admission. A final medication list is presented in Box 3. A recommendation was sent to her neurologist requesting reassessment of galantamine; at follow-up 1 year later, the drug was no longer being taken.

Box 1: Initial list of medications

Medication, dosage	Reason for use, if known
Quinapril 40 mg/d	CAD/hypertension
Amlodipine 5 mg/d	CAD/hypertension
Diltiazem ER 360 mg/d	CAD/hypertension/angina
Acebutolol 200 mg twice daily	CAD/hypertension/angina
Nitroglycerin patch 0.6 mg/h at bedtime	CAD/angina
Nitroglycerin spray 0.4 mg/spray as needed	CAD/angina
Furosemide 40 mg/d	Edema
Dipyridamole/ASA 200/25 mg twice daily	Stroke in 2008
Rosuvastatin 20 mg twice daily	Stroke in 2008
Levothyroxine 0.088 mg/d	Thyroid ablation
Tiotropium 18 µg/d	Unclear if COPD or asthma
Salbutamol 100 µg/puff, 2 puffs four times daily if needed	Unclear
Galantamine ER 16 mg/d	Dementia
Morphine 10 mg at bedtime	Pain (fibromyalgia)
Acetaminophen 650 mg every 4–6 h as needed	Pain (fibromyalgia)
Cyclobenzaprine 5 mg three times daily	Pain (fibromyalgia)
Glucosamine 500 mg twice daily	Pain (type of arthritis unclear)
Amitriptyline 75 mg at bedtime	Insomnia
Oxazepam 15 mg at bedtime	Insomnia
Lactulose 15 mL/d as needed	Constipation
Magnesium hydroxide 311 mg, 1–2 tablets at bedtime	Constipation
Fibre in water	Constipation
Bisacodyl, 2 pills as needed	Constipation
Suppository?	Constipation
Cranberry 500 mg three times daily	Bladder
Carbamazepine 200 mg twice daily	Post-stroke seizure prophylaxis
Omeprazole 20 mg/d	History of duodenal ulcer
Levofloxacin 250 mg/d	Urinary tract infection

Note: ASA = acetylsalicylic acid, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, ER = extended release.

Discussion

When multiple prescribers are involved in caring for a patient with several chronic diseases, the number of medications can quickly accumulate. Family physicians may be reluctant to modify or stop medications prescribed by consultants or started in hospital.⁴ No one person may have an overall view of how the combination of medications affects the patient, and subsequent negative additive effects may go unnoticed and unmanaged. Figure 1 illustrates the interplay between the patient's medications and the possible effects on sedation, cognition, constipation and risk of falls.

Anticholinergic load

Anticholinergic load, characterized by the cumulative effect of drugs with anticholinergic properties, can result in sedation, cognitive dysfunction, unsteadiness, orthostatic hypotension, tachycardia, dry mouth, constipation and vision problems. Ultimately, the risk of falls increases and function is impaired.^{5–11} This problem is especially important in older people because there is an age-related increase in the risk of anticholinergic toxicity owing to a decline in cholinergic transmission and increased permeability of the blood–brain barrier.¹²

With polypharmacy so prevalent in the older population, it is not surprising that an older patient could be taking several anticholinergic medications that contribute to or worsen the presentation of geriatric syndromes such as confusion and falls. In our patient's situation, several of her medications (amitriptyline, carbamazepine and cyclobenzaprine) are medium to highly anticholinergic, whereas others (diltiazem, furose-

Box 2: Complete assessment of medications for potential drug-related problems and resulting medication care plan

Potential drug-related problem	Action plan	Monitoring (team)
<p>Low blood pressure and orthostatic hypotension (and frequent falls)</p> <ul style="list-style-type: none"> • May be contributed to by cardiovascular medications: <ul style="list-style-type: none"> - Nitroglycerin patch - Furosemide - Amlodipine - Acebutolol - Quinapril - Diltiazem 	<ol style="list-style-type: none"> 1. Immediate: <ul style="list-style-type: none"> - Stop nitroglycerin patch - Decrease furosemide to 20 mg/d - Stop amlodipine 2. 1 wk later: decrease acebutolol to 100 mg twice daily; consider further decrease in future 3. Future: if needed, consider reducing quinapril, because current daily dose is at maximum 4. Future: consider reducing diltiazem ER to 240 mg/d if possible 	<ul style="list-style-type: none"> • Resolution of orthostatic hypotension • Angina/use of nitroglycerin as needed • Blood pressure target: 120/65 mm Hg to 140/90 mm Hg • Decrease in falls • Improvement in renal function: repeat serum creatinine once quinapril dose reduced
<p>Orthostatic hypotension, poor balance, excessive sedation and frequent falls</p> <ul style="list-style-type: none"> • May be contributed to by anticholinergic load: <ul style="list-style-type: none"> - Amitriptyline - Cyclobenzaprine - Morphine - Carbamazepine (not likely required for post-stroke seizure prophylaxis; may have drug accumulation owing to inhibition of cytochrome P450 3A4 enzyme by diltiazem and omeprazole) - Oxazepam (diltiazem and furosemide considered above) 	<ol style="list-style-type: none"> 1. Decrease amitriptyline to 50 mg at bedtime for 1 wk, then to 25 mg for 2 wk, then stop if possible 2. Decrease cyclobenzaprine to twice daily (morning and bedtime); reduce frequency further if possible or reduce dose to 2.5 mg; eventually stop if possible (note: patient finds this medication most effective for pain control, so may be hardest to taper) 3. Re-evaluate usefulness of morphine and taper or stop if possible 4. Consider tapering carbamazepine to 100 mg twice daily and eventually stopping 5. Once effect of above changes assessed, begin tapering oxazepam 	<ul style="list-style-type: none"> • Sleep initiation • Pain control • Resolution of orthostatic hypotension • Decrease in excessive sedation • Improvement in balance, decrease in falls • Seizure control • Thyroid-stimulating hormone levels (decrease in carbamazepine may alter levothyroxine requirements)
<p>Reduced cognition</p> <ul style="list-style-type: none"> • May be contributed to by anticholinergic load and CNS depressants (diltiazem, furosemide, amitriptyline, cyclobenzaprine, carbamazepine, morphine, oxazepam) • May not require treatment with galantamine once medication contributors tapered 	<ol style="list-style-type: none"> 1. See above for recommendations to reduce anticholinergic load, and for tapering morphine and diltiazem 2. Consider reassessing need for galantamine once above medication changes are made 	<p>Forgetfulness, difficulty finding words, apraxia</p>
<p>Constipation (stools infrequent, straining)</p> <ul style="list-style-type: none"> • May be contributed to by anticholinergic load (plus other mechanisms for diltiazem and morphine) • Requires alternate treatment, because patient is not using current regimen successfully 	<ol style="list-style-type: none"> 1. See above for recommendations to reduce anticholinergic load, and for tapering morphine and diltiazem 2. Stop lactulose, fibre supplement, bisacodyl and suppository 3. Start polyethylene glycol 3350, 15 mL in water daily 	<p>Reduced straining</p>
<p>Risk of hypermagnesemia and associated toxicity (e.g., hypotension and cramps)</p> <ul style="list-style-type: none"> • May be contributed to by magnesium therapy given reduced renal function (creatinine clearance 30 mL/min) 	<p>Stop magnesium</p>	<p>Consider checking magnesium level</p>
<p>Risk of bradycardia, atrioventricular block</p> <ul style="list-style-type: none"> • May be contributed to by combined use of acebutolol and diltiazem 	<ol style="list-style-type: none"> 1. Consider further tapering of acebutolol and possible discontinuation (as above) 2. Consider reducing diltiazem ER dose (as above) also or instead of step 1 	<ul style="list-style-type: none"> • Heart rate • Angina
<p>Omeprazole: ongoing need unclear (duodenal ulcer several years ago but no heartburn)</p>	<ol style="list-style-type: none"> 1. Stop omeprazole and start rabeprazole 10 mg/d (least expensive proton pump inhibitor on provincial drug formulary) for 2 wk, then stop 2. Use calcium carbonate or alginate or low-dose ranitidine as needed for rebound heartburn 	<p>Rebound heartburn for 2–4 wk</p>
<p>Rosuvastatin: not needed twice daily given potency and half-life</p>	<ol style="list-style-type: none"> 1. Reduce rosuvastatin to 20 mg once daily 2. Consider requesting cholesterol levels from nursing home to confirm whether patient is at LDL target 	<p>LDL target < 2.0 mmol/L</p>
<p>Salbutamol: not needed if no shortness of breath and not being used</p>	<p>Stop salbutamol</p>	<p>Shortness of breath</p>
<p>Levofloxacin: taken daily, but prescribed only for 10 days more than a month ago</p>	<p>Stop levofloxacin</p>	
<p>Concomitant amitriptyline and levofloxacin use: can cause prolonged QT interval</p>	<ol style="list-style-type: none"> 1. Taper and stop amitriptyline as suggested 2. Stop levofloxacin 	
<p>Glucosamine: benefit unlikely given questionable efficacy in osteoarthritis pain control and low dose (doses of 1.5 g/d in clinical trials)³</p>	<p>Stop glucosamine</p>	
<p>Patient at increased risk of falls but is not receiving prophylaxis for osteoporosis</p>	<ol style="list-style-type: none"> 1. Start vitamin D 1000 IU/d 2. Once constipation has resolved, start elemental calcium 500 mg twice daily (review options with patient) 3. Consider bone density scan and bisphosphonate if indicated and if renal function improves 	

Note: CNS = central nervous system, ER = extended release, LDL = low-density lipoprotein.

Box 3: Medication schedule at discharge

In the morning

- Quinapril 40 mg
- Diltiazem ER 360 mg
- Furosemide 10 mg
- Levothyroxine 0.088 mg
- Tiotropium 18 µg
- Dipyridamole/ASA 200/25 mg
- Galantamine ER 16 mg
- Cranberry complex 500 mg
- Polyethylene glycol 3350 15 mL
- Vitamin D 1000 IU

At supper

- Dipyridamole/ASA 200/25 mg
- Cranberry complex 500 mg

At bedtime

- Cyclobenzaprine 5 mg
- Oxazepam 15 mg
- Cranberry complex 500 mg
- Rosuvastatin 20 mg
- Carbamazepine 100 mg

As needed

- Nitroglycerin spray 0.4 mg/spray
- Acetaminophen 650 mg
- Saliva substitute

Note: ASA = acetylsalicylic acid, ER = extended release.

mide, morphine and oxazepam) are mildly anticholinergic.¹³ The contribution of these drugs to the patient’s symptoms is shown in Box 2, and interventions to reduce the anticholinergic load are outlined in Appendix 3D.

Additive CNS depression

As noted in Figure 1, the combination of multiple psychoactive agents likely contributed to poor balance, falls, sedation and impaired cognition in our patient. Individually and in combination, tricyclic antidepressants, muscle relaxants, benzodiazepines, anticonvulsants and opioids are known to cause excessive central nervous system (CNS) depression and increase the risk of falls in older people. The substantial sedation that may have been a result of additive CNS depressant effects made assessment of the patient’s cognition challenging.

Keeping in mind the importance of finding the lowest effective dose of any medication being used, we reduced the patient’s cyclobenzaprine dose and, when anxiety increased following cessation of carbamazepine, reinstated that drug at a small dose. This led us to suspect that the original indication might have been bipolar disorder, not post-seizure prophylaxis; however, we had difficulty assessing this without documentation from the original prescriber. Arrangements were made for follow-up with a geriatric psychiatrist after discharge. Amitriptyline was tapered and stopped; morphine was also stopped following interven-




Figure 1: Interplay between the medications of a 77-year-old woman referred to a geriatric day hospital and their possible effects on sedation, cognition, constipation and risk of falls. CNS = central nervous system.

tions to help the patient cope with pain. Recommendations were made to the patient's family physician to continue with the oxazepam tapering following discharge from the day hospital.

Multiple cardiovascular agents

Given our patient's low blood pressure and orthostatic hypotension, as well as the likely contribution of several of the cardiovascular medications to recurrent falls, we stopped the nitroglycerin patch and amlodipine and reduced the furosemide dose. Given the increased risk of acebutolol accumulation in older patients (three-fold increase in bioavailability and reduced renal excretion)¹⁴ as well as the drug's potential to cause bradycardia and atrioventricular block when taken in combination with diltiazem, the dose of acebutolol was tapered and stopped. No rebound angina or tachycardia was reported during twice-weekly monitoring. The achieved target was a blood pressure in the range of 120/65 to 140/90 mm Hg, with the lower limit established because of the patient's level of frailty and coronary artery disease.¹⁵ The patient was also able to consistently implement strategies to manage orthostatic hypotension that were taught to her by the nurse.

Other problems

We identified medications with no clear indication and those being used with questionable efficacy. For example, the patient had been taking omeprazole following remote duodenal ulcer but had no ongoing symptoms; discontinuation of the drug did not result in rebound heartburn. Administration of levofloxacin beyond 10 days may have been due to a transcription error; we notified the pharmacy to stop the medication. The salbutamol had not been used recently, which enabled us to stop it.

Poor adherence with laxative use likely contributed to the patient's continued problems with constipation. The patient demonstrated a poor understanding of proper laxative use but also had a complex medication regimen and cognitive difficulties, all of which have been shown to con-

tribute to poor adherence.¹⁶ Drug-induced constipation and poor adherence to laxative therapy meant several laxatives were started, which contributed further to the pill burden. Regular doses of magnesium hydroxide in this setting of impaired renal function increased the risk of accumulation and toxicity. Several anticholinergic medications were stopped, along with all 5 laxatives. Polyethylene glycol 3350 at a dose of 15 mL once daily was started and resolved the constipation in about 1 week. The rosuvastatin dosage was simplified to once daily to reduce pill burden. Vitamin D was added to reduce the risk of falls and maintain bone strength.¹⁷

A medication chart with indications for each medication and the reasons for stopping or lowering doses of others was provided. The patient and family were educated regarding the use of this chart as a central tool to assist all her prescribers in understanding how their medication changes could affect the patient's care. A final copy was sent to the patient's family physician with the discharge summary.

Conclusion

Polypharmacy is common among older patients. Several medications can be prescribed by different health care providers without assessment of the individual or additive impact of each drug on the overall function and well-being of the patient, or the ongoing need for each drug. In the case of our patient, several drugs caused or contributed to additive CNS depression, falls, cognitive difficulties and excessive sedation. An assessment of her medications for indication, effectiveness, safety and compliance identified drug-related contributors and allowed us to reduce her pill burden while optimizing her function and quality of life.

The close collaboration of the interprofessional health care team was instrumental. Interventions by different team members enabled subsequent medication changes, and medication changes facilitated additional interventions. Moreover, twice-weekly visits to a single location allowed the patient to receive close monitoring and ongoing support and to benefit from meaningful social interactions with her peers. Ultimately, an admission to a long-term care facility was no longer considered.

References

1. Cipolle RD, Strand LM, Morley PC, editors. *Pharmaceutical care practice: the clinician's guide*. New York (NY): McGraw-Hill; 2004.
2. Winslade N, Bajcar J. Therapeutic thought process algorithm. Ottawa (ON): National Association of Pharmacy Regulatory Authorities; 2009. Available: www.napra.org/Content_Files/Files/algorithm.pdf (accessed 2012 Oct 10).
3. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis [review]. *Cochrane Database Syst Rev* 2005;(2):CD002946.

Resources for clinicians

- A practical guide to stopping medicines in older people: www.bpac.org.nz/magazine/2010/april/stopGuide.asp
- Lee M, Jensen B, Regier L. Anticholinergics: reference list of drugs with anticholinergic effects. In: *RxFiles drug comparison charts*. 9th ed. Saskatoon (SK): Saskatoon Health Region; 2012.
- Kwan D, Farrell B. Polypharmacy — optimizing medication use in elderly patients. *Pharmacy Practice* 2012;29(2):20-5.

4. Antheriens S, Tansens A, Petrovic M, et al. Qualitative insights into general practitioners views on polypharmacy. *BMC Fam Pract* 2010;11:65.
5. Tune LE. Anticholinergic effects of medication in elderly patients. *J Clin Psychiatry* 2001;62(Suppl 21):11-4.
6. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. *BMJ* 2006;332:455-9.
7. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. *Arch Intern Med* 2008;168:508-13.
8. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. *J R Soc Med* 2000;93:457-62.
9. Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. *Arch Intern Med* 2009;169:1317-24.
10. Pasina L, Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI Study. *Drugs Aging* 2013;30:103-12.
11. Shi X, Wray DW, Formes KJ, et al. Orthostatic hypotension in aging humans. *Am J Physiol Heart Circ Physiol* 2000;279:H1548-54.
12. Hutchison LC, O'Brien CE. Changes in pharmacokinetics and pharmacodynamics in the elderly patient. *J Pharm Pract* 2007;1:4-12.
13. Lee M, Jensen B, Regier L. Anticholinergics: reference list of drugs with anticholinergic effects. In: *RxFiles drug comparison charts*. 9th ed. Saskatoon (SK): Saskatoon Health Region; 2012.
14. Roux A, Henry JF, Fouache Y, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. *Gerontology* 1983;29:202-8.
15. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med* 2006;144:884.
16. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. *Am J Geriatr Pharmacother* 2011;9:11-23.
17. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. *BMJ* 2009;339:b3692.

Competing interests: Barbara Farrell received an honorarium from the journal *Pharmacy Practice* for an article on polypharmacy; she also received an honorarium from RxFiles for preparing and presenting workshops on the management of polypharmacy. No competing interests declared by Véronique French Merkley or Wade Thompson.

Affiliations: The Geriatric Day Hospital of Bruyère Continuing Care (Farrell, French Merkley, Thompson), Ottawa, Ont.; the C.T. Lamont Primary Health Care Research Centre (Farrell), Bruyère Research Institute, Ottawa, Ont.; the Department of Family Medicine (Farrell, French Merkley), University of Ottawa, Ottawa, Ont.; and the School of Pharmacy (Thompson), University of Waterloo, Waterloo, Ont.

Contributors: Barbara Farrell and Véronique French Merkley were the clinicians involved in the care of the patient. Wade Thompson prepared the initial draft of the manuscript and conducted relevant literature searches. All of the authors revised the manuscript critically for important intellectual content and approved the final version submitted for publication.

Acknowledgement: The authors thank Ruby Grymonpré, Interprofessional Education Coordinator, University of Manitoba; Lynda Weaver, member of the Quantitative Tools Working Group of the Research and Evaluation Committee, Canadian Interprofessional Health Collaborative; and Karishma Kak, co-op student, University of Waterloo School of Pharmacy, for their help in preparing the instructions and worksheets in Appendices 3B and 3C.

This article is one of several prepared as part of a collaboration between the Geriatric Day Hospital of Bruyère Continuing Care, *CMAJ*, *Canadian Family Physician* and the *Canadian Pharmacists Journal* to assist clinicians in the prevention and management of polypharmacy when caring for older patients in their practices.

Appendix 3A: History of medication experience

Medication	Reason for use (if known)	Duration (if known)	Knowledge, efficacy, compliance, goals, safety assessment*
Quinapril 40 mg/d	CAD/hypertension	Before 2008	<ul style="list-style-type: none"> • CAD with stable angina (last episode of angina 3 mo before admission relieved with nitroglycerin) • In sinus rhythm at 72 beats/min on admission • Recent BP measurements: <ul style="list-style-type: none"> - 118/64 mm Hg sitting to 80/50 mm Hg standing - 108/69 mm Hg sitting to 88/59 mm Hg standing - 90/50 mm Hg lying to 60/36 mm Hg standing
Amlodipine 5 mg/d	CAD/hypertension	?	
Diltiazem extended release 360 mg/d	CAD/hypertension/angina	Before 2008	<ul style="list-style-type: none"> • Diagnosed by neurologist after stroke • Patient hasn't noticed anything different since starting galantamine
Acebutolol 200 mg twice daily	CAD/hypertension/angina	Before 2008	
Nitroglycerin patch 0.6 mg/h at bedtime	CAD/angina	?	<ul style="list-style-type: none"> • Stated taking 2–3 times per wk, but MAR lists daily at bedtime; thinks morphine helps sleep and decreases need for acetaminophen next day
Nitroglycerin spray 0.4 mg/spray as needed	CAD/angina	?	
Furosemide 40 mg/d	Edema	Since 2005	Mild edema in both feet noted on admission
Dipyridamole/ASA 200/25 mg twice daily	Stroke in 2008	Since 2008	Complains of a lot of bruising
Rosuvastatin 20 mg twice daily	Stroke in 2008	Since 2008	Unclear why patient taking medication twice daily
Levothyroxine 0.088 mg/d	Thyroid ablation	About 10 yr	TSH 4.71 mU/L on admission
Tiotropium 18 mcg/d	Unclear if COPD or asthma	?	Stated that if she does not take tiotropium she coughs a lot at night
Salbutamol 100 mcg, 2 puffs four times daily when needed	Unclear	?	Not used in January according to MAR; did not remember this medication
Galantamine extended release 16 mg/d	Dementia	Since 2008	<ul style="list-style-type: none"> • Stated taking 2 tablets once a week but it doesn't help
Morphine 10 mg at bedtime	Pain (fibromyalgia)	?	
Acetaminophen 650 mg every 4–6 h as needed	Pain (fibromyalgia)	?	<ul style="list-style-type: none"> • Stated that medication was recommended by rheumatologist; effective (pain goes away in half hour); if pain persists, she takes acetaminophen
Cyclobenzaprine 5 mg three times daily	Pain (fibromyalgia)	30 yr	
Glucosamine 500 mg twice daily	Pain (type of arthritis unclear)	?	Stated taking daily from own bottle but listed on MAR as regular
Amitriptyline 75 mg at bedtime	Insomnia	?	<ul style="list-style-type: none"> • To bed by 7–8 pm; awakened for evening medications about 8:30 pm but falls asleep easily; up to bathroom once nightly but falls asleep easily; wakes at 7:30 am, returns to bed until noon, then awakened for lunch; naps from 3–4 pm; has supper at 6 pm and watches television until falls asleep again; did not realize she was taking sleeping pills
Oxazepam 15 mg at bedtime	Insomnia	?	
Lactulose 15 mL/d as needed	Constipation	?	According to MAR, only took lactulose once in last month; finds taste too sweet
Magnesium hydroxide 311 mg, 1–2 tablets at bedtime	Constipation	?	Stated that this sometimes helps with constipation
Fibre in water	Constipation	?	Uses as needed if very constipated
Bisacodyl, 2 pills as needed	Constipation	?	Uses if no bowel movement for 2–3 d
Suppository?	Constipation	?	Uses if no bowel movement for 3–4 d
Cranberry 500 mg three times daily	Bladder	?	Stated taking this once daily from own supply, but MAR states three times daily
Carbamazepine 200 mg twice daily	Post-stroke seizure prophylaxis?	Since 2008	One absence seizure with TIA in March 2010; retirement home has no record of drug level since admission in 2009
Omeprazole 20 mg/d	History of duodenal ulcer	?	Stated having had a duodenal ulcer years ago but no heartburn; if she does have rare heartburn, calcium carbonate is effective
Levofloxacin 250 mg/d	Urinary tract infection	1 mo	Still taking medication, but it was prescribed for only 10 d

Note: BP = blood pressure; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; GERD = gastroesophageal reflux disease; MAR = medication administration record; TIA = transient ischemic attack; TSH = thyroid stimulating hormone.

*Patient is allergic to penicillin (tongue and mouth swelling with itchiness).

Appendix 3B: Identifying drug-related problems and developing an interprofessional medication care plan

Identifying potential drug-related problems is an important part of geriatric assessment. Signs and symptoms can be contributed to by drug therapy, and prescribing cascades can result when signs and symptoms are treated by other drugs, rather than by tapering or removing the causative medication. Medications are sometimes overused in this population, and resulting polypharmacy can affect adherence and increase the risk of adverse events. Many health care providers can contribute to resolving drug-related problems in a variety of ways. In this exercise, you will work with other health care providers to identify potential drug-related problems and to develop action plans for managing and monitoring these problems as a team.

Instructions

Read the first part of the case description and look at the patient's history of medication experience (Appendix 3A). From what you know about the case, discuss in your group the indication, effectiveness, safety and compliance with each medication. Now look at each symptom or unusual sign: What drugs might be contributing to these? As a group, use the worksheet on the next page to write down the potential drug-related problems, the actions that need to be taken to resolve them, and the monitoring parameters that should be followed to determine the outcome of interventions.

Questions for group discussion

1. Is there information missing from the case that would help you identify drug-related problems?
2. How did the members of your group decide to organize themselves to complete this task?

Resources

- Cipolle RD, Strand LM, Morley PC. *Pharmaceutical care practice: the clinician's guide*. McGraw-Hill; 2004.
- Winslade N, Bajcar J. Therapeutic thought process algorithm. Ottawa (ON): National Association of Pharmacy Regulatory Authorities; 1995. Available: www.napra.org/Content_Files/Files/algorithm.pdf (accessed 2012 Aug. 7).
- E-therapeutics, Canadian Pharmacists Association (www.pharmacists.ca/index.cfm/function/store/PublicationDetail.cfm?pPub=9)
- Lexi-Comp drug interaction tool (www.lexi.com/)
- Creatinine clearance calculation tool (www.globalrph.com/multiple_crcl.htm)

Appendix 3C: Planning interventions – When to do what and who should do it? What challenges might be anticipated?

Collaboration for interprofessional care encompasses six important competencies: team communication, person-centred care, conflict management, shared decision-making/leadership, team dynamics, and understanding roles and responsibilities. A team approach to patient care can optimize health and wellbeing – particularly in the complex frail elderly patient. Team members contribute different skill sets yet there can sometimes be role overlap. A well-functioning team should openly discuss role overlap and decide who will be doing what. Our case has focused so far on drug-related problems. Interventions have focussed primarily on medication changes. Yet, many providers can contribute to optimizing symptom management through nonpharmacological approaches. In this exercise, you will work with other interprofessional team members to plan an intervention timeline for medication changes and to identify nonpharmacological approaches and action plans for managing and monitoring symptoms that will contribute to resolving drug-related problems.

Instructions

Review the medication care plan in Box 2. Write down the order in which medication changes can be made. Think about nonpharmacological approaches that can be used concurrently to manage each sign or symptom (thus potentially affecting medication use) and who can implement and monitor these approaches. Write these down as part of the intervention timeline. If a salient health care professional is not in your group, write down which profession with whom your team would like to consult.

Questions for group discussion

1. Who should take responsibility for each pharmacological and nonpharmacological action in the intervention timeline? Who else should be consulted?
2. Who should be involved in following individual monitoring parameters?
3. Where is there role overlap? How can this be managed to maximize the team's efficiency?
4. Imagine there is a conflict about implementing part of the plan. How could the team handle it? How could conflict have been avoided?
5. Imagine the patient does not agree to an aspect of the plan. How would the team manage the patient's priorities versus their own?

Resource

- Canadian Interprofessional Health Collaborative: www.cihc.ca/

Intervention Timeline Worksheet	
Week 1	
Week 2	
Week 3	
Week 4	
Week 5	
Week 6	
Week 7	
Week 8	
Week 9	
Week 10	
Week 11	
Week 12	

Appendix 3D: Intervention timeline	
Initial pill burden: 32 pills/d Initial no. of medications: 28	
Week 1	<ul style="list-style-type: none"> • Stop nitroglycerin patch • Stop amlodipine • Decrease furosemide to 20 mg in the morning
Week 2	<ul style="list-style-type: none"> • Decrease acebutolol to 100 mg twice daily • Decrease amitriptyline to 50 mg at bedtime
Week 3	<ul style="list-style-type: none"> • Decrease carbamazepine to 100 mg twice daily • Stop levofloxacin • Stop magnesium hydroxide, fibre, bisacodyl, suppository and lactulose • Start polyethylene glycol 3350, 15 mL once daily • Decrease amitriptyline to 25 mg at bedtime • Stop salbutamol
Week 5	<ul style="list-style-type: none"> • Decrease rosuvastatin to 20 mg at bedtime • Decrease cyclobenzaprine to 5 mg in the morning and at bedtime • Decrease acebutolol to 100 mg in the morning • Stop glucosamine
Week 6	<ul style="list-style-type: none"> • Decrease cyclobenzaprine to 5 mg at bedtime • Stop amitriptyline • Start saliva substitute at bedtime when needed • Decrease acebutolol to 50 mg in the morning for 2 wk then stop • Stop omeprazole • Start rabeprazole 10 mg for 2 wk
Week 8	<ul style="list-style-type: none"> • Stop morphine • Start vitamin D supplement 1000 IU/d • Stop acebutolol • Stop rabeprazole
Week 9	<ul style="list-style-type: none"> • Stop carbamazepine • Decrease furosemide to 10 mg/d
Week 12	<ul style="list-style-type: none"> • Start carbamazepine 100 mg at bedtime
Final pill burden: 17 pills/d Final no. of medications: 17	